This finding provides a new strategy for anti-gastrointestinal infection therapy: targeting TRIM67 may promote the inflammatory response by modulating NLRP3 activity or break through the immune escape of drug-resistant bacteria by remodeling macrophage polarization, which opens up new avenues for the development of host-directed therapies. This evidence concerns the gene TRIM67 and digestive system infectious disorder.